Compare BAFN & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAFN | PLUR |
|---|---|---|
| Founded | 1999 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 36.2M |
| IPO Year | 2021 | 2001 |
| Metric | BAFN | PLUR |
|---|---|---|
| Price | $6.15 | $3.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 13.3K | 10.5K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.28% | N/A |
| EPS Growth | ★ 133.93 | 10.78 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $5.72 | $2.82 |
| 52 Week High | $19.15 | $7.13 |
| Indicator | BAFN | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 42.80 | 50.05 |
| Support Level | $6.31 | $3.50 |
| Resistance Level | $8.26 | $3.85 |
| Average True Range (ATR) | 0.35 | 0.19 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 22.69 | 53.13 |
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.